Loading asset research
Candel Therapeutics Inc. Common Stock
CADLNasdaq · USD · StocksQuote as of · Exchange session not verified$10.55
-6.93%
Today
CADL
Loading 1D prices…
Market cap
$806.9M
Volume
3.6M
52w high
$14.0052w low
$4.35Company profile
Candel Therapeutics Inc. Common Stock
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Needham, MA, United States
Employees
55
Fiscal year end
1231
CIK
1841387
Session & valuation
Open$11.32
Previous close$11.33
Day high$11.41
Day low$9.85
30-day avg. volume1.3M
Outstanding shares76.5M
Diluted EPS-$0.72
Latest annual period
P/E (trailing)-14.65
P/E (forward)-16.87
Price / book6.36
Beta-0.47
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| DBVTDBV Technologies S.A. American Depositary Shares | $744.8M | $5.6M | -2607.29% | -$1.05 | -8.02% | Buy |
| FDMT4D Molecular Therapeutics Inc. Common Stock | $727.6M | $85.2M | -164.43% | -$2.42 | -2.37% | Buy |
| AURAAura Biosciences Inc. Common Stock | $725.4M | $0.00 | — | -$1.76 | +0.29% | Buy |
| PROKProKidney Corp. Class A Ordinary Shares | $718.5M | $893K | -7725.20% | -$0.52 | -1.63% | Hold |
| SLDBSolid Biosciences Inc. Common Stock | $932.9M | $0.00 | — | -$1.99 | -4.19% | Buy |